2022
Treatment exposure-based risk-stratification for care of survivors of childhood cancer: A report from the Childhood Cancer Survivor Study.
Dinan M, Stratton K, Leisenring W, Yasui Y, Chow E, Moskowitz C, Yeh J, Noyd D, Armstrong G, Oeffinger K. Treatment exposure-based risk-stratification for care of survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Journal Of Clinical Oncology 2022, 40: 10056-10056. DOI: 10.1200/jco.2022.40.16_suppl.10056.Peer-Reviewed Original ResearchChildhood Cancer Survivor StudyHigh-risk groupHigh-risk survivorsCancer Survivor StudyRisk groupsGrade 3Hazard ratioRisk survivorsAge 20Cumulative incidenceChronic conditionsSurvivor StudyChildhood cancerAge 35Treatment exposureLow-risk survivorsFive-year survivorsHigh-risk patientsRisk stratification algorithmConfidence intervalsProportional hazards modelLong-term surveillanceCare of survivorsLate mortalityPrimary endpoint
2015
Racial variation in adjuvant chemotherapy initiation among breast cancer patients receiving oncotype DX testing
Roberts MC, Weinberger M, Dusetzina SB, Dinan MA, Reeder-Hayes KE, Troester MA, Carey LA, Wheeler SB. Racial variation in adjuvant chemotherapy initiation among breast cancer patients receiving oncotype DX testing. Breast Cancer Research And Treatment 2015, 153: 191-200. PMID: 26216535, PMCID: PMC4562432, DOI: 10.1007/s10549-015-3518-9.Peer-Reviewed Original ResearchConceptsAdjuvant chemotherapy initiationChemotherapy initiationRisk scoreODX testingCarolina Breast Cancer StudyIntermediate-risk groupRacial variationBreast cancer patientsPopulation-based studyHigh-risk groupLarger tumor sizeLow-risk groupOncotype DX testingRacial differencesNorth Carolina womenBreast Cancer StudyAdjuvant chemotherapyTumor sizeCancer patientsRelative riskRisk groupsBreast cancerPoisson regressionYounger agePhase III
2012
Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer
Reed SD, Dinan MA, Schulman KA, Lyman GH. Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer. Genetics In Medicine 2012, 15: 203-211. PMID: 22975761, PMCID: PMC3743447, DOI: 10.1038/gim.2012.119.Peer-Reviewed Original ResearchConceptsEstrogen receptor-positive breast cancerReceptor-positive breast cancerBreast cancerHormonal therapyClinicopathologic characteristicsRisk groupsEarly-stage breast cancerIncremental cost-effectiveness ratioHigh-risk characteristicsLifetime medical costsCost-effectiveness ratioLow-risk characteristicsDecision analytic modelChemotherapy useMedical costsChemotherapyPatientsHealth systemSocietal perspectiveRecurrenceCancerMultifactorial decisionTherapySupportive evidenceTreatmentCost-effectiveness of the 21-gene recurrence score assay in the setting of multifactorial decision making for chemotherapy in early-stage breast cancer.
Reed S, Dinan M, Schulman K, Lyman G. Cost-effectiveness of the 21-gene recurrence score assay in the setting of multifactorial decision making for chemotherapy in early-stage breast cancer. Journal Of Clinical Oncology 2012, 30: 1525-1525. DOI: 10.1200/jco.2012.30.15_suppl.1525.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioEstrogen receptor-positive breast cancerReceptor-positive breast cancerUse of chemotherapyRecurrence scoreBreast cancerRisk groupsEarly-stage breast cancerPatient time costsDirect medical costsLifetime direct medical costsQuality-adjusted survivalCost-effectiveness ratioHealthcare system perspectiveLower indirect costsMultifactorial decisionDecision analytic modelProbabilistic sensitivity analysesCost-effectiveness estimatesDistant recurrenceHormonal therapyClinicopathologic characteristicsDisease recurrenceAttributable costsMedical costs